2024-11-10 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis

**1. Performance Comparison with S&P 500 (VOO)**

Johnson & Johnson is a multinational pharmaceutical, medical device, and consumer packaged goods company headquartered in New Jersey, USA.

* **Cumulative return:** JNJ: 30.65%, VOO: 141.71%
* **Lag:** -111.06%
* **Relative Lag:** 0.0 (meaning JNJ has underperformed VOO by 111.06%)

**Alpha & Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|---|---|---|---|---|
| 2015-2017 | 33.7% | 10.1% | 3.5% | 0.7 |
| 2016-2018 | 28.4% | 17.5% | 3.8% | 0.7 |
| 2017-2019 | 25.9% | 17.5% | -17.1% | 0.7 |
| 2018-2020 | 13.0% | 27.5% | -26.1% | 0.7 |
| 2019-2021 | 33.9% | 27.5% | -55.9% | 0.6 |
| 2020-2022 | 21.0% | 27.5% | 3.3% | 0.5 |
| 2021-2023 | 0.1% | 16.6% | -28.7% | 0.3 |
| 2022-2024 | -8.6% | 16.6% | -33.3% | 0.2 |

This table reveals that JNJ's alpha has fluctuated significantly over the years, indicating varying performance relative to the market. Notably, JNJ has consistently displayed a beta below 1, suggesting it is less volatile than the S&P 500. However, its recent performance shows a declining beta, implying a growing disconnect from the market's movements.

**2. Recent Price Movement:**

* **Closing Price:** 156.73
* **5-day Moving Average:** 158.27
* **20-day Moving Average:** 161.56
* **60-day Moving Average:** 162.61

JNJ's current price is below its 5, 20, and 60-day moving averages, indicating a short-term downtrend.

**3. Technical Indicators:**

* **RSI:** 26.29 (oversold)
* **PPO:** -0.36 (bearish)
* **Delta_Previous_Relative_Divergence:** -4.42 (short-term downtrend)
* **Expected Return:** 0.0% (long-term, 2+ years, compared to S&P 500)

JNJ's RSI and PPO suggest that the stock is oversold and currently in a bearish trend. The negative Delta_Previous_Relative_Divergence confirms the short-term downtrend. The expected return of 0.0% indicates that JNJ is not anticipated to generate any significant outperformance compared to the S&P 500 in the long run.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |

While the latest earnings report (2024-10-23) was not provided with an earnings estimate, it is essential to remember that JNJ's revenue has been consistently around $21-22B, and it has a history of exceeding analyst expectations. However, it's crucial to note that JNJ's earnings have been consistently lower than in previous years, implying a potentially slowing growth trajectory.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $22.47B | 69.01% |
| 2024-06-30 | $22.45B | 69.40% |
| 2024-03-31 | $21.38B | 69.55% |
| 2023-12-31 | $21.39B | 68.23% |
| 2023-09-30 | $21.35B | 69.06% |

JNJ consistently displays high profit margins and generates robust revenue. While these numbers remain strong, they reflect a slight decline in the profit margin over the past several quarters, potentially pointing towards a slowing profit growth trend.

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $70.16B | 3.84% |
| 2024-06-30 | $71.54B | 6.55% |
| 2024-03-31 | $70.02B | 4.65% |
| 2023-12-31 | $68.77B | 5.89% |
| 2023-09-30 | $71.23B | 36.54% |

The ROE exhibits significant fluctuations, which can be attributed to various factors, including changes in equity and net income. Notably, the ROE for 2023-09-30 appears exceptionally high, which might be due to unusual accounting practices or temporary factors. It is crucial to analyze this outlier further to understand the underlying cause.

**6. News and Recent Issues:**

* **Recent Earnings News:** As of the last update, there were no recent earnings announcements or news that could significantly impact JNJ's stock.
* **Market Outlook:** JNJ's stock is currently facing headwinds due to its slowing growth, increased competition in the pharmaceutical sector, and a challenging economic environment. 
* **Analyst Opinions:** Some analysts are positive about JNJ's long-term prospects based on its strong brand recognition, diverse portfolio, and commitment to innovation. However, others remain cautious, highlighting the company's exposure to legal risks and its potential struggles to maintain high growth rates.

**7. Comprehensive Analysis:**

* JNJ's stock has underperformed the S&P 500 in the recent past, with a significant negative lag.
* Technical indicators suggest the stock is oversold and in a short-term downtrend.
* Although JNJ generates consistent revenue and high profit margins, its earnings growth appears to be slowing.
* While JNJ faces challenges, analysts remain optimistic about its long-term prospects due to its strong brand and diverse portfolio.

**8. Conclusion:**

JNJ is a mature company operating in a challenging market environment. While it continues to generate strong revenue and profit margins, its slowing growth and exposure to legal risks present challenges. The recent downtrend in the stock price suggests that investors may be cautious about JNJ's future prospects.

**Disclaimer:** This analysis is based on publicly available information and is for informational purposes only. It should not be considered financial advice. Please consult with a qualified financial professional before making any investment decisions. 
